Skip to search formSkip to main contentSkip to account menu

PEGINTERFERON

Known as: peginterferons 
National Institutes of Health

Related topics

Related topics

5 relations
Drug AllergyHepatitis C, ChronicHepatitis, AutoimmuneInfant, Newborn

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Highly Cited
2015
Highly Cited
2015
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
IMPORTANCE Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver… 
Highly Cited
2014
Highly Cited
2014
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus… 
Highly Cited
2014
Highly Cited
2014
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Highly Cited
2014
Highly Cited
2014
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
Highly Cited
2013
Highly Cited
2013
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Highly Cited
2012
Highly Cited
2012
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
Highly Cited
2011
Highly Cited
2011
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
BACKGROUND & AIMS Chronic hepatitis C is associated with an increased prevalence of insulin resistance, which might result from… 
Highly Cited
2010
Highly Cited
2010
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Highly Cited
2007
Highly Cited
2007
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)